protein dimerization

By Targets:	c-Myc (1) FKBP (2) HIV (1) HuR (1) PKA (1) PROTACs (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Infection (1) Metabolic Disease (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153890

NVOC cage-TMP-Halo	Others	Others
NVOC cage-TMP-Halo is a cell-permeable and photoactivatable protein dimerization inducer. NVOC cage-TMP-Halo can rapidly and reversibly control protein localization in living cells. NVOC cage-TMP-Halo can be used for dynamic cellular processes research .

HY-131015

HaXS8	Others	Others
HaXS8 is a dimerizer that can promote a covalent and irreversible intracellular dimerization of HaloTag and SNAP-tagged proteins of interest. HaXS8 does not interfere with PI3K/mTOR signaling .

HY-13992

AP20187 20+ Cited Publications B/B Homodimerizer	FKBP	Metabolic Disease
AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein (FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.

HY-160783

SRI-43265	HuR	Cancer
SRI-43265 (compound 40) is an inhibitor of human antigen R protein (HuR) dimerization, and HuR multimers have been implicated in cancer and inflammatory pathogenesis .

HY-126316

Zapalog 1 Publications Verification	FKBP	Others
Zapalog is a photocleavable small-molecule heterodimerizer that can be used to repeatedly initiate, and instantaneously terminate, a physical interaction between two target proteins. Zapalog dimerizes any two proteins tagged with the FKBP and DHFR domains until exposure to light causes its photolysis .

HY-145560

Claficapavir A1752	HIV	Infection
Claficapavir (A1752) is a specific nucleocapsid protein (NC) inhibitor with an IC₅₀ around 1 μM. Claficapavir strongly binds the HIV-1 NC (K_d=20 nM) thereby inhibiting the chaperone properties of NC and leading to good antiviral activity against the HIV-1 .

HY-150259

MDEG-541	PROTACs c-Myc	Cancer
MDEG-541 is a potent MYC-MAX degrader. MDEG-541 is a PROTAC that based on the MYC-MAX dimerization inhibitor 10058-F4 derivative 28RH and Thalidomide (HY-14658). MDEG-541 shows antiproliferative activity. MDEG-541 decreases the expression of GSPT1, MYC, GSPT2, PLK1 protein .

HY-P10319

RI-STAD-2	PKA	Cardiovascular Disease Cancer
RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting PKA activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library	424 compounds
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID). MCE provides 424 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

JAK/STAT Compound Library

424 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 424 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Cat. No.	Product Name	Target	Research Area

HY-P10376

Lucicebtide	Peptides	Cancer
Lucicebtide (Compound ST101) is a selective antagonist for CCAAT/enhancer binding protein β (C/EBPβ). Lucicebtide binds to the leucine zipper domain of C/EBPβ, prevents its dimerization, and ubiquitin-dependently degrades C/EBPβ. Lucicebtide arrests cell cycle at G0/G1 phase. Lucicebtide exhibits cytotoxicity in cancer cells. Lucicebtide exhibits good pharmacokinetic characters and inhibits tumor growth in mouse model .

HY-P10319

RI-STAD-2	PKA	Cardiovascular Disease Cancer
RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting PKA activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .

Cat. No.	Compare	Product Name	Species	Source

HY-P71203

	PHS Protein, Human (His) Pterin-4-Alpha-Carbinolamine Dehydratase; PHS; 4-Alpha-Hydroxy-Tetrahydropterin Dehydratase; dimerization Cofactor of Hepatocyte Nuclear Factor 1-Alpha; DCoH; dimerization Cofactor of HNF1; Phenylalanine Hydroxylase-Stimulating protein; Pterin Carbinolamine Dehy	Human	E. coli
	PHS protein is crucial in tetrahydrobiopterin biosynthesis and has the dual function of hindering the formation of 7-pterin and promoting quinone-BH2. It also acts as a coactivator of HNF1A-dependent transcription, affecting HNF1A dimerization and enhancing its activity. PHS Protein, Human (His) is the recombinant human-derived PHS protein, expressed by E. coli , with N-6*His labeled tag.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82484

Max Dimerization Protein 3 Antibody (YA2229)

bHLHc13; mxd3; Myx
WB, IHC-P, FC Human, Mouse, Rat

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Recombinant Proteins

Antibodies

Name
Email *

	Sorry, but the email address you supplied was invalid.